Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
30.38 EUR | +3.37% | +7.08% | +21.57% |
10:14am | AstraZeneca makes progress with Truqap and Enhertu cancer treatments | AN |
09:04am | AstraZeneca's Breast Cancer Drug Improves Progression-free Survival in Late-stage Study | MT |
Sales 2024 | 1,602B 10.22B 9.55B | Sales 2025 * | 1,761B 11.24B 10.5B | Capitalization | 9,607B 61.31B 57.3B |
---|---|---|---|---|---|
Net income 2024 | 201B 1.28B 1.2B | Net income 2025 * | 186B 1.18B 1.11B | EV / Sales 2024 | 5.72 x |
Net cash position 2024 * | 556B 3.55B 3.32B | Net cash position 2025 * | 455B 2.9B 2.71B | EV / Sales 2025 * | 5.2 x |
P/E ratio 2024 |
45.6
x | P/E ratio 2025 * |
49
x | Employees | 17,435 |
Yield 2024 |
1.05% | Yield 2025 * |
1.14% | Free-Float | 97.04% |
Latest transcript on Daiichi Sankyo Co., Ltd.
1 day | +3.37% | ||
1 week | +7.08% | ||
Current month | -0.47% | ||
1 month | +2.70% | ||
3 months | +10.92% | ||
6 months | +19.27% | ||
Current year | +21.57% |
Managers | Title | Age | Since |
---|---|---|---|
Sunao Manabe
CEO | Chief Executive Officer | 69 | 07-03-31 |
Hiroyuki Okuzawa
PSD | President | 61 | 17-03-31 |
Ken Takeshita
CTO | Chief Tech/Sci/R&D Officer | - | 21-03-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Sawako Nohara
BRD | Director/Board Member | 66 | 19-05-31 |
Kazuaki Kama
BRD | Director/Board Member | 75 | 19-05-31 |
Sunao Manabe
CEO | Chief Executive Officer | 69 | 07-03-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-29 | 29.65 | +0.88% | 160 |
24-04-26 | 29.39 | +0.41% | 0 |
24-04-25 | 29.27 | +3.06% | 135 |
24-04-24 | 28.4 | +2.16% | 150 |
24-04-23 | 27.8 | +0.40% | 65 |
Delayed Quote Deutsche Boerse AG, April 29, 2024 at 04:16 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+26.02% | 661B | |
+27.20% | 566B | |
-6.44% | 352B | |
+20.57% | 332B | |
+3.64% | 283B | |
+14.32% | 231B | |
+5.18% | 200B | |
-9.00% | 195B | |
-4.91% | 145B |
- Stock Market
- Equities
- 4568 Stock
- D4S Stock